Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

transgene

Transgene announce key partnership with Merck KGaA and Pfizer

October 12, 2016
Research and Development Cancer, France, Merck Group, Pfizer, Transgene, avelumab, head, neck

Transgene, a company that designs and developed targeted immunotherapies to treat cancer and infectious diseases, has announced a collaboration agreement …

News
takeda_world

Takeda enters $790m cancer development deal

October 11, 2016
Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …

News
cancer-389921_960_720

Kite Pharma flying high after promising Car-T trial

September 27, 2016
Manufacturing and Production, Research and Development Cancer, Cart-T, kite pharma

Cart-T cell drugs are made by genetically altering patients’ T-cells to add a component of antibodies that make them better …

News
chemo-web

Untested cancer drug suspected cause of three deaths at German alternative medicine centre

August 17, 2016
Research and Development 3-Bromopyruvate, Cancer, Germany, alternative medicine, patient deaths

The deaths of three patients at an alternative medicine clinic in Germany have prompted suspicion of a clinically untested cancer …

News
shutterstock_141299494

GSK, Roche and Novo back $86 million immuno-oncology startup

August 17, 2016
Research and Development CD47, Cancer, GSK, Novo, Roche, Tioma, oncology

Brisbane-based venture-stage biopharmaceutical company Tioma Therapeutics has announced it has raised $86 million in Series A venture financing for its …

News
merckincweb2

FDA approves MSD’s Keytruda for head and neck cancer treatment

August 8, 2016
Manufacturing and Production, Research and Development Cancer, FDA, MSD, keytruda

The US Food and Drug Administration (FDA) has approved MSD’s Keytruda (pembrolizumab) for treatment of recurrent or metastatic head and …

News
cq5dam

New drugs to utilise DNA damage response to kill cancer cells

July 26, 2016
Research and Development, Sales and Marketing AstraZeneca, Cancer, Wellcome Trust, chemotherapy, dna damage response, university of sussex

The University of Sussex is set to produce a portfolio of new cancer drugs which exploit our DNA damage response …

News
cancerstudy

Coherus BioSciences says Neulasta biosimilar shows positive topline results; shares jump

July 12, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Coherus BioSciences, biosimilar, drug trial

Shares in Coherus BioSciences (Nasdaq: CHRS) jumped to close over 27% after the company said its biosimilar copy for Amgen’s …

News

Pfizer’s blood cancer drug first to be reappraised from Cancer Drug Fund

July 7, 2016
Research and Development, Sales and Marketing Cancer, Cancer Drugs Fund, NICE, Pfizer, blood cancer, bosulif

The National Institute for Health and Care Excellence (Nice) recommended US pharma giant Pfizer’s (NYSE: PFE) Bosulif (bosutinib) to treat …

News
eisa0005

Eisai launches cancer drug Lenvatinib in Mexico

July 4, 2016
Research and Development, Sales and Marketing Cancer, Eisai, Mexico, lenvatinib, product launch

Japanese drug firm Eisai Co (TYO: 4523) said it has launched its anticancer agent Lenvima (lenvatinib mesylate) in Mexico. Lenvima …

News
mr058666-web

Merck says its Erbitux in combination with Folfox improves outcomes in colorectal cancer

July 4, 2016
Research and Development, Sales and Marketing Cancer, China, ESMO, Merck, colorectal cancer, drug trial, research, study

Merck said late-stage trials for its Erbitux (cetuximab) in combination with Folfox significantly improved progression free survival in metastatic colorectal …

News
novartis_outside_1

Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …

News
takeda_world

Takeda to return molecules/ products for Japan to Amgen

June 27, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial

Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from …

News

Novartis’ Afinitor gets EU approval to treat cancerous gastrointestinal or lung tumors

June 2, 2016
Research and Development, Sales and Marketing Afinitor, Cancer, European Commission, Novartis, regulation

Swiss drugmaker Novartis (VTX: NOVN) on Thursday said the European Commission has approved its Afinitor (everolimus) to treat cancerous gastrointestinal …

News
brexit

Remaining in the EU is vital for UK’s cancer research strength, say leading oncologists

April 27, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, EU, Europe, UK, brexit, britain, cancer research, cede, exit, implications, negative, oncology, pharma

Leading UK oncologists have written an article in the May issue of The Lancet, strongly urging Britain to remain in …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026